NASDAQ: QTTB

Q32 Bio Inc.

Healthcare | Biotechnology

No licensed closing price on file for QTTB. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Q32 Bio Inc. (NASDAQ: QTTB) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 08:00 UTC.

What Q32 Bio Inc. does

Addentum Therapeutics is a clinical-stage biotechnology company developing biologics to treat autoimmune and inflammatory diseases caused by immune dysfunction. The company's lead product candidate, bempikibart, is a monoclonal antibody designed to block signaling from interleukin-7 and thymic stromal lymphopoietin, and has been tested in patients with alopecia areata and atopic dermatitis.

Summarized from Q32 Bio Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-07-13
Return on equity	70.98%

Revenue, margins & earnings

Net income
Taxes & interest
Operating costs
Net loss year

Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-14

2026-10-14CFO and PresidentSale-1,301$10.8K
2026-10-14CEOSale-3,221$26.8K
2026-10-14Chief Scientific OfficerSale-917$7.6K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

ORBIMED ADVISORS LLC4,127,987$52.59M+83.2%
Boxer Capital Management, LLC3,149,310$40.12MNEW
Atlas Venture Life Science Advisors, LLC2,717,106$34.62M+29.9%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-12-19Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-04-25Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2022-09-08Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Wall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
zacks.com2026-07-15
Fewer than five qualifying stories — full tape in the platform →

Questions this page answers

What does Q32 Bio Inc. do?

Addentum Therapeutics is a clinical-stage biotechnology company developing biologics to treat autoimmune and inflammatory diseases caused by immune dysfunction.

When did QTTB last file with the SEC?

Q32 Bio Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-13. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 08:00 UTC. This page is also available as JSON at /api/data?ticker=QTTB and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for QTTB and 5,000+ tickers.

Create a free account — keep QTTB

For your agent

GET /api/data?ticker=QTTB

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt